Chongqing Lummy Pharmaceutical Co Ltd (300006):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Chongqing Lummy Pharmaceutical Co Ltd (300006) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8195
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Chongqing Lummy Pharmaceutical Co Ltd (Lummy) is a pharmaceutical company that provides pharmaceutical ingredients and drugs and related products. The company’s products include antibacterial drugs, antifungal drugs, tumor drugs, immune system agents, blood system agents, cardiovascular system agents, antiviral agents, and digestive system agents, among others. It also provides nervous system agents, electrolyte and acid-base, base large infusions, liver disease auxiliaries, and active pharmaceutical ingredients, among others. Lummy’s active pharmaceutical ingredients comprise atosiban acetates, thymalfasin, terlipressin acetate, desmopressin acetate, carbetocin and carbon nano-particles, among others. The company operates through its distribution network in China and Taiwan. Lummy is headquartered in Chongqing, China.

Chongqing Lummy Pharmaceutical Co Ltd (300006) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 10
Equity Offering 11
Chongqing Lummy Pharma to Raise USD141 Million in Private Placement of Shares 11
Debt Offering 12
Chongqing Lummy Pharma Plans to Raise up to USD77 Million in Private Placement of Bonds 12
Acquisition 13
Chongqing Lummy Pharma Plans to Acquire 35% Stake in Tibetan Teda Health and Medicine 13
Chongqing Lummy Pharma Acquires 30% Stake In Pharma Company For USD16 Million 14
Chongqing Lummy Pharma Completes Acquisition Of Remaining 40% Stake In Sichuan Hygien Pharma From Chongqing Venture Capital For US$7 Million 15
Chongqing Lummy Pharma To Acquire 60% Stake In Chengdu Jinxing Sanum-Kehlbeck For US$32 Million 16
Chongqing Lummy Pharmaceutical Co Ltd – Key Competitors 17
Chongqing Lummy Pharmaceutical Co Ltd – Key Employees 18
Chongqing Lummy Pharmaceutical Co Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chongqing Lummy Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Argos Therapeutics Enters into Licensing Agreement with Lummy HK 10
Chongqing Lummy Pharma to Raise USD141 Million in Private Placement of Shares 11
Chongqing Lummy Pharma Plans to Raise up to USD77 Million in Private Placement of Bonds 12
Chongqing Lummy Pharma Plans to Acquire 35% Stake in Tibetan Teda Health and Medicine 13
Chongqing Lummy Pharma Acquires 30% Stake In Pharma Company For USD16 Million 14
Chongqing Lummy Pharma Completes Acquisition Of Remaining 40% Stake In Sichuan Hygien Pharma From Chongqing Venture Capital For US$7 Million 15
Chongqing Lummy Pharma To Acquire 60% Stake In Chengdu Jinxing Sanum-Kehlbeck For US$32 Million 16
Chongqing Lummy Pharmaceutical Co Ltd, Key Competitors 17
Chongqing Lummy Pharmaceutical Co Ltd, Key Employees 18
Chongqing Lummy Pharmaceutical Co Ltd, Subsidiaries 19

List of Figures
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chongqing Lummy Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Chongqing Lummy Pharmaceutical Co Ltd (300006):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Esselte Corporation:企業の戦略・SWOT・財務分析
    Esselte Corporation - Strategy, SWOT and Corporate Finance Report Summary Esselte Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Kuwait Investment Authority:電力:M&Aディール及び事業提携情報
    Summary The Kuwait Investment Authority (KIA) is an asset management company. It offers fund management and investment management services. The company is responsible for the management and administration of the General Reserve Fund (GRF), apart from the assets of the Future Generations Fund (FGF). …
  • Bm-Bank Public Joint Stock Company
    Bm-Bank Public Joint Stock Company - Strategy, SWOT and Corporate Finance Report Summary Bm-Bank Public Joint Stock Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • TISCO Financial Group PCL:企業の戦略・SWOT・財務分析
    TISCO Financial Group PCL - Strategy, SWOT and Corporate Finance Report Summary TISCO Financial Group PCL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Transgene SA (TNG):企業の財務・戦略的SWOT分析
    Summary Transgene SA (Transgene), a subsidiary of Institut Merieux SA, is a biotechnology company that offers discovery and development of immunotherapies in the areas of cancer and infectious diseases. The company offers products such as therapeutic vaccines and oncolytic viruses. It develops targe …
  • TG Therapeutics Inc (TGTX):製薬・医療:M&Aディール及び事業提携情報
    Summary TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and autoimmune diseases. The company develops two therapies, namely, TG-1101 (ublituximab) and TGR-1202 for the tr …
  • Mauna Kea Technologies SAS (MKEA):製薬・医療:M&Aディール及び事業提携情報
    Summary Mauna Kea Technologies SAS (MKT) is an endomicroscopy device manufacturer. The company develops, manufactures and distributes tools to visualize and detect cellular abnormalities during endoscopic procedures. It provides confocal laser endomicroscopy platform. MKT’s cellvizio is an endomicro …
  • Ames Construction Inc:企業の戦略的SWOT分析
    Ames Construction Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • GS Retail Co., Ltd. (007070):企業の財務・戦略的SWOT分析
    GS Retail Co., Ltd. (007070) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Blonder Tongue Laboratories, Inc. (BDR):企業の財務・戦略的SWOT分析
    Blonder Tongue Laboratories, Inc. (BDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • hVIVO Plc (HVO):企業の財務・戦略的SWOT分析
    Summary hVIVO Plc (hVIVO), formerly Retroscreen Virology Ltd is a biopharma company that develops human-based analytical platform to accelerate drug discovery and development. The company enables organisations to discover drugs and diagnostics and accelerate new product development. It uses human di …
  • Sejal Glass Limited (SEZAL):企業の財務・戦略的SWOT分析
    Sejal Glass Limited (SEZAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Morepen Laboratories Ltd (MOREPENLAB)-製薬・医療分野:企業M&A・提携分析
    Summary Morepen Laboratories Ltd (Morepen Laboratories) is a manufacturer of active pharma ingredients and formulations. The company offers active pharma ingredients, formulation and homehealth solutions. It offers products in various formulations which include tablets, capsules, liquids and powders …
  • Termas De Puyehue S.A.:企業の戦略・SWOT・財務分析
    Termas De Puyehue S.A. - Strategy, SWOT and Corporate Finance Report Summary Termas De Puyehue S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • British Columbia Cancer Agency:医療機器:M&Aディール及び事業提携情報
    Summary British Columbia Cancer Agency (BC Cancer Agency), a subsidiary of Provincial Health Services Authority is a healthcare service center that provides comprehensive cancer control program. The center offers services such as diagnostic and therapy planning, radiation therapy, patient assessment …
  • Hampshire Trust Bank Plc:企業の戦略・SWOT・財務情報
    Hampshire Trust Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Hampshire Trust Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Strategic Oil & Gas Ltd (SOG):石油・ガス:M&Aディール及び事業提携情報
    Summary Strategic Oil & Gas Ltd (Strategic Oil & Gas) is an upstream oil and gas exploration and development company. The company acquires, explores, operates, manages, and develops crude oil and natural gas assets. It holds interests and operates its oil and gas exploration projects such as Marlowe …
  • Fiat Chrysler Automobiles NV:企業のM&A・事業提携・投資動向
    Fiat Chrysler Automobiles NV - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fiat Chrysler Automobiles NV Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • KLA-Tencor Corporation (KLAC):企業の財務・戦略的SWOT分析
    KLA-Tencor Corporation (KLAC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Companhia Energetica de Minas Gerais – CEMIG:企業の戦略・SWOT・財務情報
    Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report Summary Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆